| gap-pubmed-20260410- | Can the miR-130a/TGFβ predictive assay be validated across larger, diverse patie | open | 0.84 | 0.00 | 2026-04-10 | 0 | | translational-medicine |
| gap-pubmed-20260410- | How does miR-130a targeting of HOXA5 mechanistically regulate angiogenic process | open | 0.83 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-pubmed-20260410- | What molecular mechanisms cause sEV angiogenic properties to vary between differ | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cardiovascular-biology |
| gap-pubmed-20260410- | How do T_PEX cells contribute to neurodegeneration versus neuroprotection in chr | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms control T_PEX cell differentiation and maintenance in | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does dopamine D2/D3 receptor agonism relate to the anti-aggregation properti | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable D-520 to simultaneously disaggregate both α-syn | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What accounts for the superior diagnostic performance of p-tau181/Aβ42 ratio ove | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does p-tau181 show superior freeze-thaw stability compared to amyloid peptid | open | 0.72 | 0.00 | 2026-04-10 | 0 | | biomarker-development |
| gap-pubmed-20260410- | Why does plasma p-tau181 show stronger correlation with amyloid than tau patholo | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms mediate the relationship between plasma p-tau181 and brain patho | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do p-tau231 and p-tau217 outperform other plasma biomarkers in detecting ear | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms cause plasma p-tau231 and p-tau217 to increase before overt amyl | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do altered sphingomyelin and ganglioside concentrations mechanistically cont | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which sphingolipid alterations dri | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260410- | Why does cystatin-C binding to amyloid oligomers specifically activate TREM2 rat | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does peripheral cancer selectively increase cystatin-C secretion to therapeu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do pro-neurogenic PD microglia represent a compensatory response or a pathologic | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does NR4A2 mechanistically regulate the transition from inflammatory to pro- | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do PD microglia specifically promote neurogenesis while AD microglia do not | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the cell-type specificity of TFEB's therapeutic effects in diffe | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does microglial TFEB activation specifically enhance oligomeric Aβ clearance | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms mediate TFEB's dual regulation of autophagy enhancemen | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why is synaptic clearance aberrantly activated in AD compared to normal developm | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do TREM2, APOE, and C1q molecularly interact to promote synaptic clearance? | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which TREM2 regulates synaptic cle | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the cross-species functional conservation between human lncRNA-9 | open | 0.81 | 0.00 | 2026-04-10 | 0 | | translational-neuroscience |
| gap-pubmed-20260410- | Why do exosomal lncRNAs simultaneously regulate neuroinflammation, autophagy, an | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | molecular-neurobiology |
| gap-pubmed-20260410- | Does the oligodendrocyte-driven neuroinflammation pathway operate similarly acro | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What upstream signals activate the prosaposin-GPR37-IL-6 axis specifically in ol | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do oligodendrocytes initiate neuroinflammation in PD when microglia are trad | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Can therapeutic restoration of microglial SIRPα expression rescue synapses and c | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does SIRPα-CD47 signaling mechanistically regulate microglial engulfment of | open | 0.83 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms cause microglial SIRPα expression to decline during Al | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does Wnt/β-catenin activation specifically prevent ferroptosis rather than o | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the selective packaging of TREM2 into M2-type microglial exosome | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does exosomal TREM2 specifically activate Wnt/β-catenin signaling in recipie | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does calcium dysregulation at synapses contribute to AD and PD synaptopathy? | open | 0.86 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the specific synaptic gene and protein changes caused by defective neur | open | 0.82 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How do Aβ aggregates and hyperphosphorylated tau mechanistically disrupt neurotr | open | 0.85 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What is the causal relationship between NALL's effects on α-synuclein pathology | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | Why does NALL increase wild-type parkin expression specifically in mutant dopami | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does NALL specifically induce HTRA1 serine protease to degrade phosphorylate | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does Atremorine selectively affect dopaminergic neurotransmitters while spar | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-pubmed-20260410- | How does genetic variation determine the genotype-dependent response variability | open | 0.82 | 0.00 | 2026-04-10 | 0 | | pharmacogenomics |
| gap-pubmed-20260410- | What molecular mechanisms underlie Atremorine's dramatic dopamine enhancement in | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260410- | Why do all surviving dopaminergic neurons in Parkinson's patients retain RGS6 ex | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |